159 related articles for article (PubMed ID: 3258143)
41. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
Wise R; Griggs D; Andrews JM
Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327
[TBL] [Abstract][Full Text] [Related]
42. The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.
O'Hare MD; Felmingham D; Ridgway GL; Grüneberg RN
Drugs Exp Clin Res; 1985; 11(4):253-7. PubMed ID: 2941257
[TBL] [Abstract][Full Text] [Related]
43. [In vitro antibacterial activity of 2 new quinolones: A 56619 (difloxacin) and A 56620. Comparison with pefloxacin, ofloxacin and ciprofloxacin].
Soussy CJ; Deforges L; Le Van Thoi J; Duval J
Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):759-67. PubMed ID: 3309811
[TBL] [Abstract][Full Text] [Related]
44. In vitro activity of RO 23-6240 (AM-833): a new fluoroquinolone.
Fass RJ; Helsel VL
Diagn Microbiol Infect Dis; 1987 Apr; 6(4):293-9. PubMed ID: 3107872
[TBL] [Abstract][Full Text] [Related]
45. The in-vitro activity of EN 272, a quinolone-7-carboxylic acid, in comparison with other quinolones.
Neu HC
J Antimicrob Chemother; 1985 Jul; 16(1):43-8. PubMed ID: 3862659
[TBL] [Abstract][Full Text] [Related]
46. CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteria.
Fuchs PC; Barry AL; Jones RN; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH
Diagn Microbiol Infect Dis; 1987 Mar; 6(3):185-92. PubMed ID: 3471371
[TBL] [Abstract][Full Text] [Related]
47. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
Davies TA; Kelly LM; Hoellman DB; Ednie LM; Clark CL; Bajaksouzian S; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2000 Mar; 44(3):633-9. PubMed ID: 10681330
[TBL] [Abstract][Full Text] [Related]
48. The comparative activity of pefloxacin, enoxacin, ciprofloxacin and 13 other antimicrobial agents against enteropathogenic microorganisms.
Vanhoof R; Hubrechts JM; Roebben E; Nyssen HJ; Nulens E; Leger J; De Schepper N
Infection; 1986; 14(6):294-8. PubMed ID: 3546145
[TBL] [Abstract][Full Text] [Related]
49. Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.
Cullmann W; Stieglitz M; Baars B; Opferkuch W
Chemotherapy; 1985; 31(1):19-28. PubMed ID: 3156025
[TBL] [Abstract][Full Text] [Related]
50. Ecology of Haemophilus influenzae and Haemophilus parainfluenzae in sputum and saliva and effects of antibiotics on their distribution in patients with lower respiratory tract infections.
Foweraker JE; Cooke NJ; Hawkey PM
Antimicrob Agents Chemother; 1993 Apr; 37(4):804-9. PubMed ID: 8494378
[TBL] [Abstract][Full Text] [Related]
51. [In vitro antibacterial activity of new derivatives of pyridonecarboxylic acid, norfloxacin, ofloxacin, enoxacin and ciprofloxacin, against Vibrio cholerae O-1].
Matsushita S; Yamada S; Kudoh Y; Ohashi M
Kansenshogaku Zasshi; 1987 Mar; 61(3):292-6. PubMed ID: 3112282
[No Abstract] [Full Text] [Related]
52. In vitro activity of five new quinolones against cultivable mycobacteria.
Pattyn SR; Van Caekenberghe DL; Verhoeven JR
Eur J Clin Microbiol; 1987 Oct; 6(5):572-3. PubMed ID: 3125049
[No Abstract] [Full Text] [Related]
53. In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia.
Balkhy HH; Memish ZA; Shibl A; Elbashier A; Osoba A
East Mediterr Health J; 2005; 11(1-2):36-44. PubMed ID: 16532669
[TBL] [Abstract][Full Text] [Related]
54. A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.
Shrire L; Saunders J; Traynor R; Koornhof HJ
Eur J Clin Microbiol; 1984 Aug; 3(4):328-32. PubMed ID: 6237900
[TBL] [Abstract][Full Text] [Related]
55. The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid.
King A; Shannon K; Slegg J; Phillips I
J Antimicrob Chemother; 1986 Aug; 18(2):163-9. PubMed ID: 3463557
[TBL] [Abstract][Full Text] [Related]
56. The influence of the 4-quinolones ciprofloxacin, pefloxacin and ofloxacin on the elimination of theophylline.
Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
Pharm Weekbl Sci; 1987 Dec; 9 Suppl():S72-5. PubMed ID: 3481439
[TBL] [Abstract][Full Text] [Related]
57. [Comparative bactericidal kinetics of ciprofloxacin, ofloxacin and pefloxacin alone and in combination against strains of group D Streptococcus].
Zuccarelli M; Simeon de Buochberg M; Maillols M; Armynot du Chatelet AM; Attisso MA
Pathol Biol (Paris); 1988 May; 36(5):403-9. PubMed ID: 3136422
[TBL] [Abstract][Full Text] [Related]
58. [In vitro comparative activity of norfloxacin in the comparison of pathogenic bacteria of the urinary tract].
Carlone NA; Cuffini AM; Tullio V; Savoia D; Cavallo GP
G Batteriol Virol Immunol; 1986; 79(1-6):85-97. PubMed ID: 3479370
[TBL] [Abstract][Full Text] [Related]
59. In vitro activity of rosoxacin against Haemophilus influenzae.
Jurek EA; Weiner LB; Granato PA
Chemotherapy; 1983; 29(4):262-4. PubMed ID: 6603337
[TBL] [Abstract][Full Text] [Related]
60. Clinical use of the quinolones.
Neu HC
Lancet; 1987 Dec; 2(8571):1319-22. PubMed ID: 2890913
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
